title: Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden.
abstract: BACKGROUND
  To evaluate the pregnancy-associated risk of venous thromboembolism and the risk of stillbirth and miscarriage a multicenter, retrospective and controlled study was conducted in women carrying the homozygous factor V Leiden mutation and in an agematched control group of women from the normal population.
  
  
  METHODS
  In 64 homozygous (median age 44 years, range 21-75 years) and in 52 control women from five different centers data on venous thromboembolism and pregnancy outcome were obtained.
  
  
  RESULTS
  The 64 homozygous women had in total 212 pregnancies, the 52 control women had 118 pregnancies. In homozygous women 65% of pregnancies ended with delivery of a viable infant, 15% with fetal loss (3.3% stillbirth, 12% miscarriage) and 20% by pregnancy termination. In the control women 75% of pregnancies ended with delivery of a viable infant, 12% with fetal loss (1.7% stillbirth, 10% miscarriage) and 13% by pregnancy termination. The differences were statistically not significant. Venous thromboembolism occurred significantly more often in the homozygous women, in 4.2% (9/212) during pregnancy and in 4.7% (10/212) after delivery or pregnancy termination. None of the control women had a thromboembolic episode.
  
  
  CONCLUSIONS
  Our data indicate that women with homozygous factor V Leiden have a high probability for a favorable pregnancy outcome. The increased risk for venous thromboembolism during pregnancy and after delivery would favor heparin prophylaxis during and after pregnancy in women homozygous for factor V Leiden.
authors.affiliation: I Department of Internal Medicine, Division of Hematology/Blood Coagulation, University Hospital, Vienna, Austria. klaus.lechner@akh-wien.ac.at
authors.forename: I
authors.initials: I
authors.lastname: Pabinger
authors.forename: L
authors.initials: L
authors.lastname: Nemes
authors.forename: C
authors.initials: C
authors.lastname: Rintelen
authors.forename: S
authors.initials: S
authors.lastname: Koder
authors.forename: E
authors.initials: E
authors.lastname: Lechler
authors.forename: R M
authors.initials: RM
authors.lastname: Loreth
authors.forename: P A
authors.initials: PA
authors.lastname: Kyrle
authors.forename: I
authors.initials: I
authors.lastname: Scharrer
authors.forename: G
authors.initials: G
authors.lastname: Sas
authors.forename: K
authors.initials: K
authors.lastname: Lechner
authors.forename: C
authors.initials: C
authors.lastname: Mannhalter
authors.forename: S
authors.initials: S
authors.lastname: Ehrenforth
mesh_terms: D000328:Adult; D000368:Aged; D036861:Delivery, Obstetric; D005165:Factor V / Q000235:genetics*; D005260:Female; D006720:Homozygote; D006801:Humans; D007231:Infant, Newborn; D008875:Middle Aged; D017354:Point Mutation; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000453:epidemiology*; D011250:Pregnancy Complications, Hematologic / Q000453:epidemiology*; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D018570:Risk Assessment; D013923:Thromboembolism / Q000453:epidemiology / Q000235:genetics*
chemical_list: C095381:factor V Leiden; D005165:Factor V